Accurate antibody loop structure prediction enables zero-shot design of target-specific antibodies
Bang, Y.; Choi, Y.-A.; Gu, J.; Kwon, S.; Lee, D.; Lee, M. S.; Lee, S. J.; Lim, J.; Maeng, J. Y.; Nam, J.; Noh, J.; Oh, H.; Park, S.-Y.; Park, T.; Seo, S.; Seok, C.; Song, M. Y.; Won, J.; Woo, H.; Yang, J.; Yoon, M. J.; Bae, W.; Kim, J.; Lee, D.; Lee, J.; Lee, Y.; Yu, H.
Show abstract
Protein loops, characterized by their versatile structures with varying sizes and shapes, can recognize a wide range of targets with high specificity and affinity. The variable loops of the antibody complementarity-determining region (CDR) are particularly crucial for immune responses and therapeutic applications due to their effective target recognition capabilities. Accurate structure prediction of these antibody loops is essential for the efficient in silico design of target-binding antibodies for therapeutic or industrial use. However, predicting antibody loop structures is challenging due to the lack of evolutionary information from related proteins. Thus, a successful ab initio structure prediction method, which operates without structural templates or related sequences, is crucial for the effective design of antibody loop-mediated interactions. This study demonstrates that highly accurate antibody loop structure prediction enables the effective zero-shot design of target-binding antibody loops. The performance of loop design has been shown to depend on the accuracy of ab initio loop structure prediction, as tested with two versions of our design model. The high affinity, diversity, novelty, and specificity of the antibody loops designed with these new methods were validated experimentally on four target proteins.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Improving antibody thermostability based on statistical analysis of sequence and structural consensus data 94%
- Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies 93%
- Accelerated Antibody Discovery Targeting the SARS-CoV-2 Spike Protein for COVID-19 Therapeutic Potential 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.